DanielC.JavittMDPhD

Psychopharmacology

Director, Division of Experimental Therapeutics Director, Columbia Conte Center for Schizophrenia Research Professor of Psychiatry and Neuroscience Columbia University College of Physicians and Surgeons New York, NY Director, Division of Schizophrenia Research Nathan Kline Institute for Psychiatric Research Orangeburg, NY

Join to view full profile

Dr. Javitt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Javitt's full profile

Already have an account?

Office
1051 Riverside Dr
Unit 21
New York, NY 10032
Phone+1 212-543-5475

Fax+1 212-543-5668

Education & Training

Montefiore Medical Center/Albert Einstein College of MedicineResidency, Psychiatry, 1986 - 1987
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Psychiatry, 1984 - 1986
Albert Einstein College of MedicineClass of 1983

Certifications & Licensure

NY State Medical License 1984 - 2025
MD State Medical License 2009 - 2010
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Safety and Effectiveness of D-serine in Schizophrenia Start of enrollment: 2006 Mar 01
Completed
Phase 2
A Multicenter Study of NAP (AL-108) in Schizophrenia Start of enrollment: 2007 Jul 01
Completed
Phase 2
Sodium Oxybate in Schizophrenia With Insomnia Start of enrollment: 2008 May 01
Completed
Phase 2
Biomarkers in Schizophrenia Start of enrollment: 2009 Jun 01
Completed
Phase 2
D-serine for the Schizophrenia Prodrome Start of enrollment: 2009 Mar 01
Completed
Phase 2
N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia Start of enrollment: 2012 Mar 01
Unknown status
Phase 2
TDCS for Auditory Hallucinations in Schizophrenia Start of enrollment: 2013 May 01
Completed
Not Applicable
Biomarker Assessment of Glutamatergic Target Engagement Start of enrollment: 2014 May 01
Completed
Phase 4
Neuroimaging in Patients Undergoing TMS for Depression Start of enrollment: 2017 Apr 30
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Impact of Early Auditory Processing on Negative Symptom Response to Cognitive Remediation for Schizophrenia.
Alice M Saperstein, Ryan Brennan, Min Qian, Daniel C Javitt, Alice Medalia
Schizophrenia Bulletin. 2025-02-21
Lower-level oculomotor deficits in schizophrenia during multi-line reading: Evidence from return-sweeps.
Andriana L Christofalos, Madison Laks, Stephanie Wolfer, Elisa C Dias, Daniel C Javitt
Quarterly Journal of Experimental Psychology. 2024-07-01
Biomarkers for Cognitive Control, Response Inhibition, Aggressivity, Impulsivity, and Violence.
Matthew J Hoptman, Ragy R Girgis, Daniel C Javitt
Advances in Neurobiology. 2024-01-01

Journal Articles

A Multicenter Study of Ketamine Effects on Functional Connectivity: Large Scale Network Relationships, Hubs and Symptom Mechanisms
Ragy R Girgis, Richard J Maddock, John D Ragland, Daniel C Javitt, Cameron S Carter, Joshua T Kantrowitz, Jeffrey Lieberman, John H Krystal, Lawrence S Kegeles, Willia..., ScienceDirect
American Psychiatric Association Publishing
Cheryl M Corcoran, Daniel C Javitt, National Institutes of Health
Sensory and Cross-Network Contributions to Response Inhibition in Patients with Schizophrenia
Daniel C Javitt, Matthew J Hoptman, ScienceDirect

Press Mentions

Pharma Consortium Publishes Results of Large EEG/ERP Biomarker Study in Subjects with Schizophrenia and Healthy VolunteersMarch 16th, 2023
CUIMC Update - Sept. 13, 2021September 13th, 2021
NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. And Big Rock Partners Acquisition Corp (Nasdaq:BRPA)May 25th, 2021
Join now to see all

Grant Support

A Schizophrenia Extension Study for the NKI Rockland Sample II project: An Open Resource of Multimodal Brain, Physiology & Behavior from a Community Lifespan SampleNATHAN S. KLINE INSTITUTE FOR PSYCH RES2024–2029
Use of alpha-frequency deep transcranial interference stimulation (tIS) to understand and modify temporal dynamics of face emotion recognition and social/affective function.COLUMBIA UNIVERSITY HEALTH SCIENCES2024–2028
Auditory event-related potentials as in vivo preclinical assays of circuit engagement for E/I-based therapeutic developmentNATHAN S. KLINE INSTITUTE FOR PSYCH RES2023–2028
Glutamatergic mechanisms of psychosis and target engagementNEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC2020–2027
Neural Mechanisms of Reading Dysfunction in SchizophreniaCOLUMBIA UNIVERSITY HEALTH SCIENCES2020–2025
Neural Mechanisms of Reading Dysfunction in SchizophreniaCOLUMBIA UNIVERSITY HEALTH SCIENCES2020–2025
Neural Mechanisms of Reading Dysfunction in SchizophreniaCOLUMBIA UNIVERSITY HEALTH SCIENCES2020–2025
Neural Mechanisms of Reading Dysfunction in SchizophreniaCOLUMBIA UNIVERSITY HEALTH SCIENCES2020–2025
Early Cortical Processing in SchizophreniaNATHAN S. KLINE INSTITUTE FOR PSYCH RES1993–2025
Early Cortical Processing In SchizophreniaNational Institute Of Mental Health2003–2012
Multimodal Assessment Of Sensory Processing Dysfunction In SchizophreniaNational Institute Of Mental Health2011
AdministrativeNational Institute Of Mental Health2011
The Conte Center For Schizophrenia ResearchNational Institute Of Mental Health2010–2011
The Conte Center For Schizophrenia ResearchNational Institute Of Mental Health2009–2010
Multimodal Assessment Of Sensory Processing Dysfunction In SchizophreniaNational Institute Of Mental Health2009–2010
AdministrativeNational Institute Of Mental Health2009–2010
Sensory Processing Dysfunction In Neuropsychiatric IllnessNational Institute Of Mental Health2008–2010
Phencyclidine Abuse &Psychosis: Biomedical MechanismsNational Institute On Drug Abuse2007–2010
Pk/Pd, Dose Finding And Adjunctive Treatment StudiesNational Institute Of Mental Health2005–2009
D-Serine Treatment Of SchizophreniaNational Institute Of Mental Health2005–2009
Methods For Sensory Assessment In SchizophreniaNational Institute Of Mental Health2008
Dopamine In A Primate Model Of Glutamate HypofunctionNational Institute Of Mental Health2004–2008
Neurophysiological NMDA Dysfunction In SchizophreniaNational Institute Of Mental Health1997–2006
Phencyclidine Abuse And Psychoses: Biomedical MechanismsNational Institute On Drug Abuse2001–2005
Mechanisms Of Cognitive Dysfunction In SchizophreniaNational Institute Of Mental Health2001–2005
Neuroanatomic Basis Of Cognitive ERP Deficit In SchizophFogarty International Center2001–2003
Treatment Of Negative Symptoms And Cognitive ImpairmentsNational Institute Of Mental Health2000–2003
High-Density ERP Mapping &FmriNational Center For Research Resources2002
Phencyclidine Abuse And Psychosis--Biomedical MechanismsNational Institute On Drug Abuse1998–2000
Intracortical Mechanisms Of COG Dysfunction In SchizophrNational Institute Of Mental Health1997–1999
Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1996–1997
Assessment Of Glycine Treatment In SchizophreniaNational Institute Of Mental Health1996–1997
Phencyclidine Abuse &Psychosis--Biomedical MechanismsNational Institute On Drug Abuse1995
Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1995
Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1993–1995
NMDA Receptors In Processing Contingent Aep GenerationNational Institute Of Mental Health1990–1991
Phencyclidine Psychopharmacology--SchizophreniaNational Institute Of Mental Health1986–1990